Goldfarb Branham Law Firm Investigating Claims for Talecris Biotherapeutics Holdings Shareholders

DALLAS--(BUSINESS WIRE)-- Goldfarb Branham is investigating Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) for shareholders due to the company’s agreement to be acquired by Spanish healthcare company Grifols. The national securities law firm is concerned about both the price and process used to sell Talecris. Stockholders with information or concerns about this buyout are encouraged to contact shareholder lawyer Hamilton Lindley by telephone at 877-583-2855 or by email at [email protected].

Although at least one analyst has a target price of $30.00 per share, TLCR shareholders will receive only $26.16 in the proposed partial cash and stock deal. Regrettably, the offer price is only a small premium over the $24.41 Talecris stock price on January 22, 2010. Approximately $7.00 of the $26.16 that shareholders will receive is actually non-voting Grifols stock. On news of the buyout, Grifols stock plummeted 8.5% in just one day.

If you have information or concerns about this transaction, contact attorney Hamilton Lindley at 877-583-2855 or by email at [email protected]. Goldfarb Branham focuses its practice on merger and acquisition litigation, in addition to other shareholder lawsuits. In fact, lawyers at Goldfarb Branham have been counsel on 100 merger and acquisition cases – including some of the largest in the United States. The firm is not afraid to give advice – stand by it – and go to the courthouse to get results.


Goldfarb Branham LLP
Hamilton Lindley, 214-583-2233
Toll Free: 877-583-2855
Fax: 214-583-2234
[email protected]

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Legal


Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.